checkAd

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

  • Experienced life sciences executive Dr Ruben Herrendorff appointed as CEO
  • Serial biotech entrepreneur Dr Ulf Grawunder appointed as Board member
  • Targeted therapy aims to treat autoimmune disease whilst avoiding serious, long-term complications of the current non-selective immunosuppression

BASEL, Switzerland, Nov. 30, 2022 /PRNewswire/ -- NXI Therapeutics[1], the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr Ruben Herrendorff as its new CEO to drive the next stage of its development. Ruben was previously co-founder and CEO of Polyneuron Pharmaceuticals AG, a blue-chip VC-backed biotech developing a new antigen-specific technology platform to tackle antibody-mediated autoimmune diseases.

The Company also announced that it has appointed Dr Ulf Grawunder to its Board of Directors. Ulf is a successful serial biotech entrepreneur, who has founded and exited two biotech companies since 2004: 4-Antibody (sold to US-based Agenus) and NBE-Therapeutics (sold to Boehringer Ingelheim). Recently, Ulf became Managing Partner at Swiss Viopas Venture Consulting and he has co-founded T-CURX, which is focused on the development of next-generation CAR-T cell therapies for cancer patients, where he has recently assumed the position of CEO.

NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, Switzerland and is committed to creating tomorrow's safe immunotherapies by leveraging a novel targeted approach in T cell immunology. NXI Therapeutics is pioneering the development of selective immunosuppressants that target the coronin 1 pathway, which regulates those T cell immune responses that play a key role in graft rejection and autoimmunity, while leaving the protective responses against infections and vaccination intact. Coronin 1 depletion in preclinical models allows long-term acceptance of genetically unrelated organ transplants, prevents Graft vs Host Disease (GvHD), protects from several autoimmune disorders, and at the same time allows to maintain a normal life span without infections and emergence of cancer, a frequent complication of contemporary immunosuppressants. Thus, modulating coronin 1 signaling holds great potential for more efficient and safer treatments for autoimmune diseases, as well as for transplantation, by realizing powerful targeted immunosuppression that preserves immunocompetence.

Seite 1 von 3



0 Kommentare
Nachrichtenquelle: PR Newswire (engl.)
 |  149   |   |   

Schreibe Deinen Kommentar

Disclaimer

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage Experienced life sciences executive Dr Ruben Herrendorff appointed as CEOSerial biotech entrepreneur Dr Ulf Grawunder appointed as Board memberTargeted therapy aims to treat autoimmune disease whilst avoiding serious, long-term complications of the …

Nachrichten des Autors

120 Leser
112 Leser
112 Leser
108 Leser
108 Leser
108 Leser
108 Leser
108 Leser
104 Leser
104 Leser
348 Leser
292 Leser
288 Leser
176 Leser
160 Leser
152 Leser
148 Leser
136 Leser
136 Leser
136 Leser
592 Leser
580 Leser
508 Leser
472 Leser
444 Leser
400 Leser
356 Leser
348 Leser
292 Leser
288 Leser
2424 Leser
1886 Leser
1749 Leser
1247 Leser
1217 Leser
1191 Leser
1063 Leser
990 Leser
982 Leser
956 Leser